ESTRO 38 Abstract book

S803 ESTRO 38

uterine cervical cancer. This study involved a small sample size of a single institution, so further validation is required prior to incorporating the NLR as a prognostic indicator. EP-1482 Stereotactic rt in ovarian cancer: multicentric retrospective pooled analysis (MITO-RT project) G. Macchia 1 , G.R. D’Agostino 2 , A. Fodor 3 , A.M. Cerrotta 4 , R. Autorino 5 , D. Russo 6 , E. Perrucci 7 , A. Zamagni 8 , A. Di Stefano 9 , C. Iftode 2 , S. Cilla 10 , A.G. Morganti 8 , C. Aristei 7 , N. Di Muzio 3 , M. Scorsetti 2 , F. Deodato 1 , G. Scambia 11 , V. Valentini 5 , G. Ferrandina 11 1 Università Cattolica S. Cuore- Fondazione Giovanni Paolo II, Radiotherapy Unit, Campobasso, Italy ; 2 Humanitas Clinical and Research Hospital, Radiotherapy and Radiosurgery, Rozzano - Milan, Italy ; 3 San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Universitario “A. Gemelli”- Università Cattolica del Sacro Cuore, Department of Radiotherapy, Roma, Italy ; 6 Ospedale "Vito Fazzi"-, Radiotherapy Unit, Lecce, Italy ; 7 University of Perugia and Perugia General Hospital, Radiation Oncology Section, Perugia, Italy ; 8 Radiation Oncology Center, Department of Experimental- Diagnostic and Specialty Medicine - DIMES- University of Bologna-, Bologna, Italy ; 9 Fondazione di Ricerca e Cura “Giovanni Paolo II”- Università Cattolica del Sacro Cuore, Gynecologic Oncology Unit, Campobasso, Italy ; 10 Fondazione di Ricerca e Cura “Giovanni Paolo II”- Università Cattolica del Sacro Cuore, Medical Physics Unit, Campobasso, Italy ; 11 Fondazione Policlinico Universitario «A. Gemelli»- Università Cattolica del Sacro Cuore-, Department of Women’s and Children’s health, Rome, Italy Purpose or Objective Stereotactic body radiotherapy (SBRT) represents an interesting opportunity in the treatment of ovarian cancer (OC) isolated recurrences or residual lesions after systemic treatment, and a valid tool to lengthen the free time of re-challenge with platinum. Studies on this topic are sporadic and with few cases. Aim of this multicentric retrospective pooled analysis was to collect the largest unselected real-life dataset of OC patients treated with SBRT in the attempt to define the safety and efficacy. Secondary objectives were to identify the best dose/fractionation regimen in terms of local control as well as to describe acute and late toxicities. Material and Methods Eight Italian cancer Centers were firstly started the project giving their adhesion to this retrospective pooled analysis. A specific data-set for standardized data collection for ovarian cancer SBRT treatment was developed. Participants were required to fill a data sets including: age, histotype, site of irradiation, previous treatments, best response, toxicity as well as technical/dosimetric data about SBRT treatment. Results Data on 73 OC patients (median age: 63.5, range 40-83) carrying a total of 120 lesions were considered suitable for analysis. Between 2005 and 2018 all patients underwent SBRT in single or multiple fractions with a median biological equivalent dose (BEDα/β 10) of 76.8 Gy (range 7.5-262.5). Patient and treatment characteristics as well as acute toxicity are detailed in Table 1. Safety. 52 patients (71.3%) did not experience acute toxicity, the others 21 (28.7%) experienced low grade acute toxicity with no patient showing > grade 2 toxicity. With a median follow-up of 18 months (range: 1 - 120), 68 patients (93.1%) did not experienced late toxicity, the others 5 (6.9%) experienced low grade late toxicity with no patient showing > grade 2 toxicity. Efficacy. On a per-lesion basis, the 12-and 24-months actuarial local control inside SBRT field were 88.3% and Italy ; 4 IRCCS Istituto Nazionale dei Tumori, Radiotherapy Unit, Milan, Italy ; 5 Policlinico

The 1-year overall survival rate was 47.2 % (estimated median survival: 9 months). Five patients were alive, of whom 4 were disease-free at last follow-up. Of 6 patients with oligometastases, 3 were alive and 2 were considered no evidence of disease at last follow-up (median survival time in this group: 31 months). Significant prognostic factors for survival included <4 lung metastases (P = 0.035), unilateral vs. bilateral lung metastases (P = 0.039), primary tumor diameter <100 mm (P <0.001), and ECOG performance status <1 at initial treatment (P = 0.015). Lung metastases <10 mm (P = 0.14) and concurrent chemotherapy (P = 0.07) did not significantly affect survival. No acute or late toxicities > Grade 3 were associated with treatment. Conclusion RT is safe and effective for patients with lung metastases from uterine cervical cancer. Patients with oligometastases may especially benefit from aggressive treatment. EP-1481 Leukocytosis and Neutrophil to Lymphocyte Ratio: Prognostic Factors in Uterine Cervical Cancer? S. Garcia 1 , R. Costa Lago 1 , G. Almeida 1 , D. Rodrigues 1 , M.P. Fontes 1 , G. Pinto 1 1 Centro Hospitalar de São João, Serviço de Radioterapia, Porto, Portugal Purpose or Objective Even though the incidence and mortality of invasive uterine cervical cancer have steadily decreased, this disease is still the second most common type of cancer in females worldwide and the leading cause of cancer deaths in women in developing countries. Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematological parameters have emerged as potential indicators of a worse outcome in this patient group. In a cohort of cervical cancer patients treated with radiation therapy alone (RT) or concurrent chemoradiation therapy (CCRT) and brachytherapy, we report on prognostic significance of pretreatment hematologic parameters including leukocytosis and neutrophil to lymphocyte ratio (NLR). Material and Methods Ninety-seven cervical cancer patients were retrospectively identified from a single cancer institution´s database (CHSJ - Centro Hospitalar de São João). A database was created with information obtained from patients' clinical records. Hematologic parameters were categorized as: leukocytosis (white blood cells count > 10 x 10 9 /L) and NLR (high ratio > 5). A demographic analysis of the study sample was performed. The impact of the hematological parameters on progression free survival (PFS) and overall survival (OS) was assessed using the Kaplan-Meier plots and the log rank test for univariate analysis and the Cox regression for multivariate analysis. Statistical analysis was performed with SPSSv24. Results Of the 97 patients, 10 were in the leukocytosis group and 31 were in the high NLR group. Median age at diagnosis was 58 years and median follow-up time was 56 months. Median PFS was 46 months and median OS was 54 months. Comparing the various groups of patients regarding hematological parameters, the high NRL was significantly associated with worse survival (PFS: 89 vs 118 months, p=0.009; OS: 90 vs 118 months, p=0.004). Leukocytosis did not show a statistically significant impact on PFS and OS. Multivariate analysis showed that both high NRL and leukocytosis were significant prognostic factors for OS (p=0.022, CI 95%). Conclusion Results showed that patients with a high NRL had significantly shorter PFS and OS than those with a low NLR. The leukocytosis and NLR may be promising parameters on which to base the choice of a therapeutic strategy to treat